Vext Science (FRA:VV5) Moat Score: 2/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VV5 Vext Science Inc FRA:VV5
62 GF Score
Price €0.09
GF Value €0.92
! 3 Warning Signs
View Full Analysis

What is Vext Science Moat Score?

Vext Science FRA:VV5 -36.03% 62 Moat Score is 2 as of Jul. 14, 2026. GuruFocus rates FRA:VV5 with a GF Score™ of 62/100 and a GF Value™ of €0.92. The stock has 3 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Vext Science ranks better than 81.57% on this metric.

Vext Science has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Vext Science has No Moat: Vext Science operates in a highly competitive cannabis industry with minimal barriers to entry and limited brand strength. It lacks significant cost advantages or customer loyalty to establish a moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vext Science might have No Moat - Very weak/transient advantages.

Vext Science  (FRA:VV5) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vext Science Moat Score Related Terms

FRA:VV5 vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vext Science Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vext Science's Moat Score distribution charts can be found below:

* The bar in red indicates where Vext Science's Moat Score falls into.


FRA:VV5
62GF Score
Vext Science Inc FRA:VV5
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Vext Science (FRA:VV5) has a Moat Score of 2 as of Jul. 14, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Vext Science ranks #190 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 18.4%.
Is Vext Science's Moat Score too high?
Vext Science's current Moat Score is 2. Based on the distribution chart, Vext Science ranks #190 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vext Science has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #190 out of 1031 companies for Moat Score. This places Vext Science in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Vext Science's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current Moat Score of 2. The stock's GF Value™ is €0.92, compared to a current price of €0.09 — trading 90.5% below its estimated fair value. The current Moat Score is 2. Vext Science's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current Moat Score is 2 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vext Science (FRA:VV5) Overvalued in 2026?

Based on GuruFocus' analysis, Vext Science stock appears to be undervalued. The current stock price of €0.09 is trading 90.5% below its estimated GF Value™ of €0.92.

Key valuation signals for FRA:VV5:

  • Moat Score: 2
  • GF Value™: €0.92 vs. price of €0.09 (90.5% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vext Science Business Description

Other Exchanges VEXTF:USAVEXT:Canada
Address 4152 N. 39th Avenue, Admin, Phoenix, AZ, USA, 85019
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
62GF Score

Get the complete analysis for FRA:VV5

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price
€0.92
GF Value